Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Midkine (MK) is a 13-kDa heparin-binding growth factor and cytokine that plays a critical role in cell proliferation, survival, migration, and angiogenesis. It is highly expressed during embryogenesis and is upregulated in various inflammatory diseases and cancers. In the context of psoriasis research, recombinant midkine protein is used as a research tool to investigate the pathogenesis of the disease. Studies have shown that midkine promotes keratinocyte proliferation and angiogenesis by regulating the production of Vascular Endothelial Growth Factor A (VEGF-A) through the Notch2/HES1/JAK2-STAT5A signaling pathway. While midkine is considered a potential therapeutic target for inhibition (e.g., via monoclonal antibodies), the recombinant protein itself is primarily utilized in laboratory settings to exacerbate disease models and evaluate signaling mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on midkine.